Huawei is bringing its cardiovascular monitoring technology to Peru with the launch of the Huawei Watch D3, a lightweight smartwatch featuring an integrated mechanical airbag for ambulatory blood pressure tracking over 24 hours.
The wearable lands in the Peruvian market as a specialized tool for continuous cardiovascular management. Weighing approximately 40 grams with a slim 11.3 millimeter body, the device integrates a 25.5 millimeter mechanical air bag inside its strap. This inflatable system applies controlled compression around the wrist to capture accurate pulse readings while minimizing physical discomfort during daily routines or overnight rest.
Ambulaory Blood Pressure Monitoring and 24-Hour Tracking
Ambulatory Blood Pressure
The Huawei Watch D3 addresses the need for round-the-clock observation. The device supports 24-hour ambulatory blood pressure monitoring, aligning with clinical practice guidelines from the European Society of Hypertension that recommend measurement intervals of 15 to 30 minutes with high validity rates. Medical Certification and Exercise Monitoring Capabilities
CE Certification and Huawei Health App Integration
Blood pressure fluctuates naturally under the influence of physical activity, rest, and stress. To capture these shifts safely, the Huawei Watch D3 incorporates dedicated tools for measuring pressure before and after physical exertion, complying with international standards to maintain accuracy even when heart rates climb. The resting blood pressure, pre- and post-exercise, and ambulatory monitoring modes have earned CE certification as medical devices. Beyond isolated metrics, the ecosystem aggregates data into broader wellness summaries. These longitudinal trends feed directly into the Huawei Health app, supplying structured records that can assist patients during consultations with healthcare professionals.
European Society of Cardiology Congress and Terve Research Platform
The hardware rollout builds on broader scientific engagement by the technology firm. As the Huawei Watch D3 transitions from its European debut to the Peruvian market, it provides a regulated, lightweight alternative for patients managing hypertension outside traditional clinical settings.